Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.70 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1774951 | 0.99 | HTR6 (0.69) | HTR6HTR2CHTR1ADRD2HTR7 | |
| SCHEMBL1774802 | 0.96 | HTR6 (0.76) | HTR6HTR2CHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL1774991 | 0.94 | HTR6 (0.74) | HTR6HTR2CHTR1ADRD2HTR7 | |
| SCHEMBL1778549 | 0.90 | HTR6 (0.69) | HTR6HTR2CHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL1781144 | 0.89 | HTR6 (0.67) | HTR6HTR2CHTR1ADRD2HTR7 | |
| SCHEMBL1776222 | 0.88 | HTR6 (0.68) | HTR6HTR2CHTR1A | |
| SCHEMBL1778034 | 0.87 | HTR6 (0.67) | HTR6HTR2CHTR1ADRD2HTR7 | |
| SCHEMBL1777317 | 0.87 | HTR6 (0.74) | HTR6HTR2C | |
| SCHEMBL1780383 | 0.87 | HTR6 (0.92) | HTR6HTR2CHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL1780081 | 0.87 | HTR6 (0.67) | HTR6HTR2CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | claimed |
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | HTR6 2109/4885HTR2C 1245/4885HTR1A 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.